Vector Biolabs specializes in the production and development of adeno-associated virus (AAV) and adenovirus vectors for research and commercial applications. Their custom AAV production services allow clients to design and construct viral vectors tailored to specific research needs, with a typical turnaround time of 4-5 weeks. The company boasts an extensive catalog of approximately 90,000 AAV products, which include options derived from human, mouse, and rat genomes, as well as synthetic AAVs. Vector Biolabs also provides comprehensive support in vector design, cloning, packaging, and purification, ensuring high-quality outcomes for various applications, including gene delivery and gene expression studies.

In addition to AAV services, Vector Biolabs offers custom adenovirus services, which encompass similar processes of vector design, cloning, and production. Their expertise extends to providing ready-to-use recombinant adenoviruses and AAVs, including tools for gene silencing and CRISPR/Cas9 applications. The company emphasizes the importance of selecting the appropriate viral vector for specific research goals, offering guidance on serotypes and promoters to optimize gene delivery. With over 20 years of experience in the field and a commitment to quality control, Vector Biolabs has established itself as a leading provider of viral vector solutions, serving a diverse range of institutions and research needs.

United States

Vector Biolabs, a Fortis Life Sciences Company, is focused on developing robust gene delivery products through use of proprietary tools and technologies. Vector has been the leading CMO in research, discovery, and preclinical viral vector production for over 20 years, and has constructed and produced more than thirty thousand AAVs and adenovirus capsids.

Vector Biolabs

Company Details